原发性胆汁性肝硬化患者血清抗GP210和抗SP100检测的临床意义*

doi:10.3969/j.issn.1672-5069.2011.02.018

实用肝脏病杂志 ›› 2011, Vol. 14 ›› Issue (2): 132-134.doi: 10.3969/j.issn.1672-5069.2011.02.018

原发性胆汁性肝硬化患者血清抗GP210和抗SP100检测的临床意义^*

唐映梅,包维民,尤丽英,江洪娟,杨晋辉

650033 昆明市昆明医学院第二附属医院肝胆胰内科/肝病中心（唐映梅，尤丽英，江洪娟，杨晋辉）；云南省第一人民医院普外一科（包维民）

收稿日期:2010-11-25 出版日期:2011-04-10 发布日期:2016-04-15
通讯作者: 杨晋辉，E-mail:scheldon_t@tom.com
作者简介:唐映梅女，36岁，医学博士，主治医师。主要从事慢性肝病的基础及临床研究。E-mail:tangyingmei_med@163.com
基金资助:
云南省自然科学基金（2010CD170）；云南省科技计划及国际合作基金资助项目（编号2006GH14）；云南省自然科学基金资助项目（编号2010C0014R）

Clinical significance of serum anti-SP100 and anti-GP210 detection in diagnosis of patients with primary biliary cirrhosis

TANG Yingmei，BAO Weimin，YOU Liying，et al.

The Center of Liver Diseases，the 2nd Affiliated Hospital，Kunming Medical College，Kunming 650033

Received:2010-11-25 Online:2011-04-10 Published:2016-04-15

摘要/Abstract

摘要： 目的研究抗GP210和抗SP100检测诊断原发性胆汁性肝硬化（PBC）的临床意义。方法采用免疫印迹法检测118例自身免疫性肝病患者血清抗GP210和抗SP100。结果 71例PBC和47例非PBC患者两抗体阳性率无显著性差异；在PBC患者，抗GP210、抗SP100和两抗体同时阳性诊断的特异性分别为40.2%、76.6%和82.4%，敏感度分别为26.8%、11.2%和10.2%；不同病理分期PBC患者血清抗体阳性率无显著性差异（P>0.05）。结论抗GP210和抗SP100的检测并不能提高诊断PBC的效能。

关键词: 原发性胆汁性肝硬化, 自身免疫性肝炎, 抗GP210, 抗SP100

Abstract: Objective To explore the clinical significance of serum anti-SP100 and anti-GP210 in diagnosis of patients with primary biliary cirrhosis. Methods Serum anti-GP210 and anti-SP100 were detected in 71 patients with PBC and 47 with autoimmune hepatitis，or AIH/PBC overlap syndrome. Results The positive rates in patients with PBC or with non-PBC were not significantly different；in patients with PBC，the specificities of anti-GP210，anti-SP100 and anti-GP210/anti-SP100 were 40.2%，76.6% and 82.4%，while the sensitivities were 26.8%，11.2% and 10.2%；there was no significant difference in the positive rates of the two antibodies or both in patients with different pathological stage of liver diseases. Conclusions The detection of serum anti-GP210 and anti-SP100 do not improve the diagnosis of patients with PBC.

Key words: Primary biliary cirrhosis, Autoimmune hepatitis, Anti-GP210, Anti-SP100

唐映梅,包维民,尤丽英,江洪娟,杨晋辉. 原发性胆汁性肝硬化患者血清抗GP210和抗SP100检测的临床意义^*[J]. 实用肝脏病杂志, 2011, 14(2): 132-134.

TANG Yingmei，BAO Weimin，YOU Liying，et al.. Clinical significance of serum anti-SP100 and anti-GP210 detection in diagnosis of patients with primary biliary cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2011, 14(2): 132-134.

参考文献

[1] LINDOR KD，GERSHWIN ME，POUPON R，et al. AASLD practice guidelines. Primary biliary cirrhosis[J]. Hepatology，2009，50:291-308.
[2] MURATORI P，MURATORI L，GERSHWIN ME，et al.‘True’ antimitochondrial antibody-negative primary biliary cirrhosis，low sensitivity of the routine assays，or both[J]. Clin Exp Immunol，2004，135:154-158.
[3] ALBERT JC. Autoantibodies as prognostic markers in autoimmune liver disease[J]. Dig Dis Sci，2010，55:2144-2126.
[4] ALVAREZ F，BERG PA，BIANCHI FB，et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis[J]. J Hepatol，1999，31:929-938.
[5] CHAZOUILLERSE O，WENDUM D，SERFATY L，et al. Primary biliary cirrhosis autoimmune hepatitis overlap syndrome: clinical features and response to therapy[J]. Hepatology，1998，28:296-301.
[6] CHAPMAN R，FEVERY J，KALL CO，et al. Diagnosis and mangement of primary sclerosing cholangitis[J]. Hepatology，2010，51:660-678.
[7] MURATORI P，MURATORI L，FERRARI R，et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis[J]. Am J Gastroenterol，2003，98:431-437.
[8] WORMAN HJ，COURVALIN JC. Antinuclear antibodies specific for primary biliary cirrhosis[J]. Autoimmun Rev，2003，2:211-217.
[9] MIKIEWICZ P，BUWANESWARAN H，COLTESCU C，et al. Value of autoantibody analysis in the differential diagnosis of chronic cholestatic liver disease[J]. Clin Gastroenterol Hepatol， 2009，7:1355-1360.
[10] MURATORI P，MURATORI L，CASSANI F，et al. Anti-multiple nuclear dots（anti-MND）and anti-SP100 antibodies in hepatic and rheumatological disorders[J]. Clin Exp Immunol，2002，127:172-175.
[11] GAO L，TIAN X，LIU B，et al. The value of antinuclear antibodies in primary biliary cirrhosis[J]. Clin Exp Med，2008，8:9-15.
[12] MILKIEWICZ P，BUWANESWARAN H，COLTESCU C，et al. Value of autoantibody analysis in the differential diagnosis of chronic cholestatic liver disease[J]. Clin Gastroenterol Hepatol， 2009，7（12）:1355-1360.
[13] NAKAMURA M，KONDO H，MORI T，et al. Anti-gp210 and anticentromere antibodies are different risk factors for the progression of primary biliary cirrhosis[J]. Hepatology，2007，45:118-127.
[14] CZAJA AJ，MURATORI P，MURATORI L，et al. Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis[J]. Liver Int，2004，24:322-329.
[15] BOGDANOS DP，BAUM H，BUTLER P，et al. Association between the primary biliary cirrhosis specific anti-sp100 antibodies and recurrent urinary tract infection[J]. Dig Liver Dis， 2003，35:801-805.

原发性胆汁性肝硬化患者血清抗GP210和抗SP100检测的临床意义^*

Clinical significance of serum anti-SP100 and anti-GP210 detection in diagnosis of patients with primary biliary cirrhosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	汪道伟, 方坚, 范凌. 自身免疫性肝炎患者血清IL-21和趋化因子水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 844-847.
[2]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[3]	周炎仪, 阳灿. 雷公藤多甙片联合异甘草酸镁治疗自身免疫性肝炎患者疗效初步研究[J]. 实用肝脏病杂志, 2019, 22(3): 365-368.
[4]	彭小燕,徐莉娟,刘鹏,祁双宝,孙一鸣. 自身免疫性肝炎患者血清腺苷脱氨酶水平与肝组织炎症活动程度的关系及对治疗应答的影响^*[J]. 实用肝脏病杂志, 2019, 22(2): 200-203.
[5]	林兰,沈敏,阮健文. 自身免疫性肝炎患者肝组织程序性死亡受体1表达及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(2): 204-207.
[6]	郭晓霞, 郭琲婷, 孔祥璐. 脾切除对原发性胆汁性肝硬化小鼠肝组织纤维化影响研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 837-841.
[7]	刘映川, 赵鹏程, 游亭, 邓红英, 薛江凤. 熊去氧胆酸联合维生素D治疗PBC患者疗效和外周血T淋巴细胞亚群的变化[J]. 实用肝脏病杂志, 2018, 21(6): 907-910.
[8]	夏庚综述, 祁飞, 杨晋辉审校. 自身免疫性肝炎诱发因素研究进展[J]. 实用肝脏病杂志, 2018, 21(6): 983-986.
[9]	刘进国, 王暴魁. 复方鳖甲软肝片联合丁二磺酸腺苷蛋氨酸和熊去氧胆酸治疗PBC患者疗效及其对血清肝纤维化指标的影响*[J]. 实用肝脏病杂志, 2018, 21(3): 340-343.
[10]	刘靓懿, 宿冬远. 药物性肝损伤与自身免疫性肝炎临床和肝组织病理学特征比较研究[J]. 实用肝脏病杂志, 2018, 21(3): 463-464.
[11]	秦维, 陈宇萍, 杨昭, 祝素平, 霍玉玲, 李木松. 原发性胆汁性肝硬化患者肝组织转化生长因子β-1表达水平变化[J]. 实用肝脏病杂志, 2018, 21(2): 237-240.
[12]	陈小君, 宋洋. UDCA联合维生素D治疗原发性胆汁性肝硬化患者外周血T细胞亚群变化及其对疗效的影响[J]. 实用肝脏病杂志, 2018, 21(1): 80-83.
[13]	雷静. 利肝隆联合甘草酸二铵治疗自身免疫性肝炎患者疗效及其安全性研究[J]. 实用肝脏病杂志, 2018, 21(1): 108-109.
[14]	陶明玲, 张世斌, 吴燕京, 郭晓红, 丁惠国. 原发性胆汁性肝硬化患者食管静脉曲张特点及其无创预测指标研究^*[J]. 实用肝脏病杂志, 2017, 20(4): 439-442.
[15]	刘复娜, 刘江奎, 沈毅慧. 泼尼松龙联合熊去氧胆酸治疗原发性胆汁性肝硬化患者疗效初步研究[J]. 实用肝脏病杂志, 2017, 20(4): 443-446.